论文部分内容阅读
在肿瘤发生和演进中发挥驱动作用的基因改变常可作为特异性诊断标志物、分子分型的依据和治疗新靶点。丝氨酸蛋白酶抑制因子Kazal1型(SPINK1)又被称为胰腺分泌性胰酶抑制因子(PSTI)或肿瘤相关性胰酶抑制因子(TATI),是一种由56个氨基酸残基组成的分泌性多肽,主要作用是抑制胰蛋白酶原等多种丝氨酸蛋白酶原活性。最近的研究提示,SPINK1可能通过发挥类生长因子作用,促进前列腺癌的生长和侵袭。SPINK1和前列腺癌患者的预后密切相关,可能是某些恶性程度高的前列腺癌的潜在治疗靶点。本课题组研究初步证实SPINK1的过表达与前列腺癌患者的临床不良预后呈正相关。本文通过对现阶段前列腺癌中SPINK1的基础及临床转化研究作简要综述,旨在强调其在前列腺癌的预后评价和治疗靶点选择上的重要意义。
Gene mutations that play a driving role in tumorigenesis and evolution can often be used as specific diagnostic markers, molecular typing basis and treatment of new targets. The serine protease inhibitor Kazal1 (SPINK1), also known as pancreatic secretory trypsin inhibitor (PSTI) or tumor associated trypsin inhibitor (TATI), is a secreted peptide consisting of 56 amino acid residues, The main role is to inhibit trypsinogen and other serine protease activity. Recent studies suggest that SPINK1 may promote the growth and invasion of prostate cancer by acting as a growth factor. The prognosis of patients with prostate cancer is closely related to SPINK1 and may be a potential therapeutic target for some malignant prostate cancers. The research group initially confirmed that SPINK1 overexpression and prostate cancer patients with poor clinical prognosis was positively correlated. This article briefly reviews the basic and clinical research of SPINK1 in prostate cancer at present, and aims to emphasize the importance of SPINK1 in prostate cancer prognosis evaluation and treatment target selection.